Data from the TROPION-Breast01 trial support the FDA approval of datopotamab deruxtecan for those with metastatic HR–positive, HER2-negative breast cancer.
Approval Alert | Datopotamab Deruxtecan in Metastatic HR+/HER2– Breast Cancer
Advertisement
Advertisement
Trending on CancerNetwork
1
Palbociclib Maintenance Extends PFS in HR+/HER2+ Advanced Breast Cancer
2
Optimizing Treatment Sequencing Before Third Line CAR T-Cell Therapy in Multiple Myeloma
3
New ASCO Guideline Offers Recommendations for Smoldering Multiple Myeloma
4
FDA Clears IND for Investigational Program in Recurrent High-Grade Glioma
5